Indaptus Therapeutics Inc
NASDAQ:INDP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Indaptus Therapeutics Inc
Retained Earnings
Indaptus Therapeutics Inc
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Indaptus Therapeutics Inc
NASDAQ:INDP
|
Retained Earnings
-$81.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-7%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Retained Earnings
-$15.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Retained Earnings
$13.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Retained Earnings
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Retained Earnings
$13.6B
|
CAGR 3-Years
28%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Retained Earnings
$35.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
45%
|
|
Indaptus Therapeutics Inc
Glance View
Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. The company designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.
See Also
What is Indaptus Therapeutics Inc's Retained Earnings?
Retained Earnings
-81.3m
USD
Based on the financial report for Dec 31, 2025, Indaptus Therapeutics Inc's Retained Earnings amounts to -81.3m USD.
What is Indaptus Therapeutics Inc's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-7%
Over the last year, the Retained Earnings growth was -34%. The average annual Retained Earnings growth rates for Indaptus Therapeutics Inc have been -39% over the past three years , 17% over the past five years , and -7% over the past ten years .
